All In Biotech

Free tool

FAERS Monitor: Proglycem

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 017453 or its brand name (Proglycem, Diazoxide). Reports on generic versions are filed under their own applications.

Reports

737

Serious

643

87% of reports

Hospitalization

312

Death reported

98

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective134
  • hypoglycaemia101
  • off label use73
  • hyperglycaemia46
  • drug ineffective for unapproved indication38
  • drug interaction30
  • product use in unapproved indication29
  • oedema peripheral25
  • malignant neoplasm progression23
  • nausea23
  • death22
  • insulinoma22
  • necrotising colitis20
  • oedema20
  • vomiting20

Reports by year received

View as table
YearReports
20047
20059
20066
200712
20088
20098
201012
201113
201216
201332
201431
201556
201631
201730
201831
201945
202029
202155
202252
202364
202463
202596
202631

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,422 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
insulinomaSignal224054.62609.674,566
necrotising colitisSignal20457.8296.18,529
hypoglycaemiaSignal10159.549.75,757
hyperglycaemiaSignal4636.127.31,534
drug ineffective for unapproved indicationSignal3819.814.5660
oedemaSignal2010.56.8163
malignant neoplasm progressionSignal236.44.3100
oedema peripheralSignal255.94.096
drug interactionSignal305.43.8104
product use in unapproved indicationSignal293.32.346
drug ineffectiveSignal1342.92.5176
off label useSignal732.41.959
vomiting201.20.81
nausea230.80.61
death220.70.52

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.